Interaction of the Protein Transduction Domain of HIV-1 TAT with Heparan Sulfate: Binding Mechanism and Thermodynamic Parameters

Biophysical Journal

Volumn 86, Issue 1 I, 2004, Pages 254-263

  Ziegler, André ^a   Seelig, Joachim ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; PROTEIN TRANSDUCTION DOMAIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CALORIMETRY; CELL MEMBRANE; CELL SURFACE; CHARGE NEUTRALIZATION REACTION; CHEMICAL REACTION; CIRCULAR DICHROISM; COMPLEX FORMATION; CROSS LINKING; ELECTRICITY; ENTHALPY; ENTROPY; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOTHERMAL TITRATION CALORIMETRY; LIGHT SCATTERING; MACROMOLECULE; MOLECULAR MECHANICS; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REACTION ANALYSIS; SIGNAL TRANSDUCTION; STOICHIOMETRY; STRUCTURE ANALYSIS; THERMODYNAMICS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0346688716     PISSN: 00063495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3495(04)74101-6     Document Type: Article

References (56)

1. Albini, A., R. Benelli, M. Presta, M. Rusnati, M. Ziche, A. Rubartelli, G. Paglialunga, F. Bussolino, and D. Noonan. 1996. HIV-TAT protein is a heparin-binding angiogenic growth factor. Oncogene. 12:289-297.
2. Barillari, G., L. Buonaguro, V. Fiorelli, J. Hoffman, F. Michaels, R. C. Gallo, and B. Ensoli. 1992. Effects of cytokines from activated immune cells on vascular cell-growth and HIV-1 gene-expression-implications for AIDS-Kaposi's Sarcoma pathogenesis. J. Immunol. 149:3727-3734.
3. Bayer, P., M. Kraft, A. Ejchart, M. Westendorp, R. Frank, and P. Rosch. 1995. Structural studies of HIV-1 TAT protein. J. Mol. Biol. 247:529-535.
4. Belting, M. 2003. Heparin sulfate proteoglycan as a plasma membrane carrier. Trends Biochem. Sci. 28:145-151.
5. Carey, D. J. 1997. Syndecans: multifunctional cell-surface co-receptors. Biochem. J. 327:1-16.
6. Churcher, M. J., C. Lamont, F. Hamy, C. Dingwall, S. M. Green, A. D. Lowe, P. J. G. Butler, M. J. Gait, and J. Karn. 1993. High-affinity binding of TAR RNA by the HIV type-1 TAT protein requires base-pairs in the RNA stem and amino-acid residues flanking the basic region. J. Mol. Biol. 230:90-110.
7. Clavel, F., M. Guyader, D. Guetard, M. Salle, L. Montagnier, and M. Alizon. 1986. Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature. 324:691-695.
8. Derossi, D., S. Calvet, A. Trembleau, A. Brunissen, G. Chassaing, and A. Prochiantz. 1996. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271:18188-18193.
9. Eguchi, A., T. Akuta, H. Okuyama, T. Senda, H. Yokoi, H. Inokuchi, S. Fujita, T. Hayakawa, K. Takeda, M. Hasegawa, and M. Nakanishi. 2001. Protein transduction domain of HIV-1 TAT protein promotes efficient delivery of DNA into mammalian cells. J. Biol. Chem. 276:26204-26210.
10. Fawell, S., J. Seery, Y. Daikh, C. Moore, L. L. Chen, B. Pepinsky, and J. Barsoum. 1994. TAT-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA. 91:664-668.
11. Fowlkes, J. L., and D. M. Serra. 1996. Characterization of glycosaminoglycan-binding domains present in insulin-like growth factor-binding protein-3. J. Biol. Chem. 271:14676-14679.
12. Frankel, A. D., and C. O. Pabo. 1988. Cellular uptake of the TAT protein from human immunodeficiency virus. Cell. 55:1189-1193.
13. Frankel, A. D., and J. A. Young. 1998. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67:1-25.
14. Gius, D., A. M. Vocero-Akbani, M. Wei, and S. F. Dowdy. 1997. TAT mediated protein transduction into cells: examination phosphorylation status of the retinoblastoma protein in vivo. Int. J. Radiat. Oncol. Biol. Phys. 39:160-160.
15. Green, M., and P. M. Loewenstein. 1988. Autonomous functional domains of chemically synthesized human immunodeficiency virus TAT transactivator protein. Cell, 55:1179-1188.
16. Ho, A., S. R. Schwarze, S. J. Mermelstein, G. Waksman, and S. F. Dowdy. 2001. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res. 61:474-477.
17. Howard, T. M., and S. Rasheed. 1996. Genomic structure and nucleotide sequence analysis of a new HIV type 1 subtype A strain from Nigeria. AIDS Res. Hum. Retrovir. 12:1413-1425.
18. Huang, L., H. Farhood, N. Serbina, A. G. Teepe, and J. Barsoum. 1995. Endosomolytic activity of cationic liposomes enhances the delivery of human immunodeficiency virus-1 trans-activator protein (TAT) to mammalian cells. Biochem. Biophys. Res. Commun. 217:761-768.
19. Laspia, M. F., A. P. Rice, and M. B. Mathews. 1989. HIV-1 TAT protein increases transcriptional initiation and stabilizes elongation. Cell. 59:283-292.
20. Lewin, M., N. Carlesso, C. H. Tung, X. W. Tang, D. Cory, D. T. Scadden, and R. Weissleder. 2000. TAT peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18:410-414.
21. Lewis, G. N., M. Randall, K. S. Pitzer, and L. Brewer. 1961. Thermodynamics, 2nd Ed. McGraw-Hill, New York. 524.
22. Lindgren, M., M. Hallbrink, A. Prochiantz, and U. Langel. 2000. Cell-penetrating peptides. Trends Pharmacol. Sci. 21:99-103.
23. Long, K. S., and D. M. Crothers. 1995. Interaction of HIV type-1 TAT-derived peptides with TAR RNA. Biochemistry. 34:8885-8895.
24. Luo, Y., S. J. Madore, T. G. Parslow, B. R. Cullen, and B. M. Peterlin. 1993. Functional analysis of interactions between TAT and the transactivation response element of human immunodeficiency virus type 1 in cells. J. Virol. 67:5617-5622.
25. Mabrouk, K., J. Vanrietschoten, E. Vives, H. Darbon, H. Rochat, and J. M. Sabatier. 1991. Lethal neurotoxicity in mice of the basic domains of HIV and SIV REV proteins-study of these regions by circular-dichroism. FEBS Lett. 289:13-17.
26. Mai, J. C., H. M. Shen, S. C. Watkins, T. Cheng, and P. D. Robbins. 2002. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J. Biol. Chem. 277:30208-30218.
27. Mann, D. A., and A. D. Frankel. 1991. Endocytosis and targeting of exogenous HIV-1 TAT protein. EMBO J. 10:1733-1739.
28. Martinho, R. G., S. Castel, J. Urena, M. Fernandez-Borja, R. Makiya, G. Olivercrona, M. Reina, A. Alonso, and S. Vilaro. 1996. Ligand binding to heparan sulfate proteoglycans induces their aggregation and distribution along actin cytoskeleton. Mol. Biol. Cell. 7:1771-1788.
29. Mitchell, D. J., D. T. Kim, L. Steinman, C. G. Fathman, and J. B. Rothbard. 2000. Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 56:318-325.
30. Nath, A., K. Psooy, C. Martin, B. Knudsen, D. S. K. Magnuson, N. Haughey, and J. D. Geiger. 1996. Identification of a human immunodeficiency virus type-1 TAT epitope that is neuroexcitatory and neurotoxic. J. Virol. 70:1475-1480.
31. Orsini, M. J., C. M. Debouck, C. L. Webb, and P. G. Lysko. 1996. Extracellular human immunodeficiency virus type-I TAT protein promotes aggregation and adhesion of cerebellar neurons. J. Neurosci. 16:2546-2552.
32. Pooga, M., M. Hallbrink, M. Zorko, and U. Langel. 1998. Cell penetration by transportan. FASEB J. 12:67-77.
33. Prochiantz, A. 2000. Messenger proteins: homeoproteins, TAT et al. Curr. Opin. Cell Biol. 12:400-406.
34. Rana, T. M., and K. T. Jeang. 1999. Biochemical and functional interactions between HIV-1 TAT protein and TAR RNA. Arch. Biochem. Biophys. 365:175-185.
35. Roy, C., C. Knaak, P. Garvie, B. Limmer, and J. Campione-Piccardo. 1989. Plasmid library for the transcription of RNA probes complementary to the entire genome of the human immunodeficiency virus type 1 (HIV-1). Biochem. Cell. Biol. 67:510-515.
36. Rusnati, M., D. Coltrini, P. Oreste, G. Zoppetti, A. Albini, D. Noonan, F. D. diFagagna, M. Giacca, and M. Presta. 1997. Interaction of HIV-1 TAT protein with heparin-role of the backbone structure, sulfation, and size. J. Biol. Chem. 272:11313-11320.
37. Rusnati, M., G. Tulipano, D. Spillmann, E. Tanghetti, P. Oreste, G. Zoppetti, M. Giacca, and M. Presta. 1999. Multiple interactions of HIV-1 TAT protein with size-defined heparin oligosaccharides. J. Biol. Chem. 274:28198-28205.
38. Rusnati, M., G. Tulipano, C. Urbinati, E. Tanghetti, R. Giuliani, M. Giacca, M. Ciomei, A. Corallini, and M. Presta. 1998. The basic domain in HIV-1 TAT protein as a target for polysulfonated heparin-mimicking extracellular TAT antagonists. J. Biol. Chem. 273:16027-16037.
39. Salminen, M. O., C. Koch, E. Sandersbuell, P. K. Ehrenberg, N. L. Michael, J. K. Carr, D. S. Burke, and F. E. McCutchan. 1995. Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain-reaction. Virology. 213:80-86.
40. Sandgren, S., F. Cheng, and M. Belting. 2002. Nuclear targeting of macromolecular polyanions by an HIV-TAT derived peptide-role for cell-surface proteoglycans. J. Biol. Chem. 277:38877-38883.
41. Schwarze, S. R., A. Ho, A. Vocero Akbani, and S. F. Dowdy. 1999. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 285:1569-1572.
42. Schwarze, S. R., K. A. Hruska, and S. F. Dowdy. 2000. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol. 10:290-295.
43. Seelig, J. 1997. Titration calorimetry of lipid-peptide interactions. Biochim. Biophys. Acta. Rev. Biomembr. 1331:103-116.
44. Sodroski, J., R. Patarca, C. Rosen, F. Wong Staal, and W. Haseltine. 1985. Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III. Science. 229:74-77.
45. Stein, S., A. Weiss, K. Adermann, P. Lazarovici, J. Hochman, and H. Wellhoner. 1999. A disulfide conjugate between anti-tetanus antibodies and HIV (37-72) TAT neutralizes tetanus toxin inside chromaffin cells. FEBS Lett. 458:383-386.
46. Tanford, C. 1961. Physical Chemistry of Macromolecules. John Wiley & Sons, New York. 532.
47. Torchilin, V. P., R. Rammohan, V. Weissig, and T. S. Levchenko. 2001. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. USA. 98:8786-8791.
48. Tyagi, M., M. Rusnati, M. Presta, and M. Giacca. 2001. Internalization of HIV-1 TAT requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276:3254-3261.
49. van Holde, K. E., W. C. Johnson, and S. P. Ho. 1998. Principles of Physical Biochemistry. Prentice Hall, Upper Saddle River, New Jersey. 605.
50. Violini, S., V. Sharma, J. L. Prior, M. Dyszlewski, and D. Piwnica-Worms. 2002. Evidence for a plasma membrane-mediated permeability barrier to TAT basic domain in well-differentiated epithelial cells: lack of correlation with heparan sulfate. Biochemistry. 41:12652-12661.
51. Vives, E., P. Brodin, and B. Lebleu. 1997. A truncated HIV-1 TAT protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272:16010-16017.
52. Wadia, J. S., and S. F. Dowdy. 2002. Protein transduction technology. Curr. Opin. Biotechnol. 13:52-56.
53. Weeks, K. M., C. Ampe, S. C. Schultz, T. A. Steitz, and D. M. Crothers. 1990. Fragments of the HIV-1 TAT protein specifically bind TAR RNA. Science. 249:1281-1285.
54. Wender, P. A., D. J. Mitchell, K. Pattabiraman, E. T. Pelkey, L. Steinman, and J. B. Rothbard. 2000. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. USA. 97:13003-13008.
55. Wiseman, T., S. Williston, J. F. Brandts, and L. N. Lin. 1989. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal. Biochem. 179:131-137.
56. Ziegler, A., X. Li Blatter, A. Seelig, and J. Seelig. 2003. Protein transduction domains of HIV-1 and SIV TAT interact with charged lipid vesicles. Binding mechanism and thermodynamic analysis. Biochemistry. 41:9185-9194.